



HAL
open science

Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia

Thomas Ernst, Joannah Score, Claire Hidalgo-Curtis, Michael Wn Deininger, Peter M Lackie, William B Ershler, John M Goldman, Nicholas C.P. Cross, Francis Hector Grand

► To cite this version:

Thomas Ernst, Joannah Score, Claire Hidalgo-Curtis, Michael Wn Deininger, Peter M Lackie, et al.. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. British Journal of Haematology, 2011, 153 (1), pp.43. 10.1111/j.1365-2141.2010.08457.x . hal-00612830

HAL Id: hal-00612830

<https://hal.science/hal-00612830>

Submitted on 1 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia



Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-00999
Manuscript Type:	Short Reports
Date Submitted by the Author:	24-Jun-2010
Complete List of Authors:	Ernst, Thomas; Universitätsklinikum Jena, Klinik für Innere Medizin II Score, Joannah; University of Southampton, Wessex Regional Genetics Laboratory Hidalgo-Curtis, Claire; University of Southampton, Wessex Regional Genetics Laboratory Deininger, Michael; Oregon Health and Science University, Hematology Lackie, Peter; University of Southampton, Infection Inflammation and Immunity Ershler, William; Harbor Hospital, Hematology/Immunology Unit Goldman, John; Imperial College London, Haematology Cross, Nicholas; University of Southampton, Salisbury District Hospital, Wessex Regional Genetics Laboratory Grand, Francis; University of Southampton, Wessex Regional Genetics Laboratory
Key Words:	ABL, ACUTE LEUKAEMIA, IMATINIB

1
2
3 **Identification of *FOXP1* and *SNX2* as novel *ABL1* fusion partners in acute**
4
5
6 **lymphoblastic leukaemia**
7
8
9

10
11 Thomas Ernst¹, Joannah Score², Michael Deininger³, Claire Hidalgo-Curtis², Peter Lackie⁴,
12
13 William B Ershler⁵, John M Goldman⁶, Nicholas C.P. Cross² and Francis H. Grand²
14
15

16
17
18
19 ¹Universitätsklinikum Jena, Klinik für Innere Medizin II
20 Jena, Germany
21

22
23 ²Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United
24 Kingdom
25

26
27 ³Oregon Health and Science University, Hematology
28 Portland, Oregon, United States
29

30
31 ⁴University of Southampton, Infection Inflammation and Immunity
32 Southampton, United Kingdom
33

34
35 ⁵Harbor Hospital, Hematology/Immunology Unit
36 Baltimore, Maryland, United States
37

38
39 ⁶Harbor Hospital, Hematology/Immunology Unit
40 Baltimore, Maryland, United States
41
42
43
44

45 Keywords: ABL1, FOXP1, SNX2, ALL, acute lymphoblastic leukaemia
46
47
48
49

50 Running title: *FOXP1-ABL1* and *SNX2-ABL1* fusion genes in B-ALL
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Corresponding author:**
7

8 Francis H. Grand, PhD
9

10 Wessex Regional Genetics Laboratory
11

12 University of Southampton
13

14 Salisbury SP2 8BJ
15

16 United Kingdom
17
18
19

20
21
22 Tel: +(44) 1722 429080
23

24 Fax: +(44) 1722 338095
25

26
27 E-Mail: F.H.Grand@soton.ac.uk
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summary

We have identified two novel *ABL1* fusion genes in two patients with B-cell acute lymphoblastic leukaemia associated with a t(3;9)(p12;q34) and a t(5;9)(q23;q34), respectively. Molecular analysis revealed a *FOXP1-ABL1* fusion for the t(3;9) and a *SNX2-ABL1* fusion for the t(5;9). The fusions were confirmed by specific amplification of the genomic breakpoints using reverse transcription polymerase chain reaction (RT-PCR). The identification of ALL with rare *ABL1* fusion partners is important because the leukaemia may respond to tyrosine kinase inhibitors in the same way as ALL patients with a classical *BCR-ABL1* fusion gene.

Introduction

Constitutively activated mutants of the non-receptor tyrosine kinase ABL1 play a central role in the pathogenesis of clinically and morphologically distinct chronic and acute leukaemias (Chase & Cross, 2006). By far the most frequent and best-studied ABL1 fusion gene is *BCR-ABL*, which results from an acquired reciprocal $t(9;22)(q34;q11)$ (Shtivelman *et al*, 1985; Ben-Neriah *et al*, 1986). The $t(9;22)(q34;q11)$ is found in virtually all patients with chronic myeloid leukaemia (CML), in approximately 20% of adults with B-cell acute lymphoblastic leukaemia (ALL), and in rare cases of acute myeloid leukaemia (Fröhling & Döhner 2008). The second most frequent and biologically distinct *ABL1* fusion gene is *NUP214-ABL1* in T-ALL (Graux *et al*, 2004). Remarkably, this fusion is generated by circularisation of the 500 kb genomic region from *ABL1* to *NUP214* and subsequent extrachromosomal (episomal) amplification. Other *ABL1* fusion genes have been described but are uncommon. The *ETV6-ABL1* fusion gene is the product of a $t(9;12)(q34;p13)$ and is found in occasional patients with acute leukaemias or atypical CML (Papadopoulos *et al*, 1995; Golub *et al*, 1996; Andreasson *et al*, 1997). *EML1-ABL1* was found in a single female patient with T-ALL and a cryptic $t(9;14)(q34;q32)$ (De Keersmaecker *et al*, 2005). Recently, *RCSD1*, *ZMIZ1* and *SFPQ* were identified as novel *ABL1* fusion partners in single cases of B-ALL (De Braekeleer *et al*, 2007; Soler *et al*, 2008; Hidalgo-Curtis *et al*, 2008).

Imatinib is a specific inhibitor of several tyrosine kinases including ABL1 and induces long-term complete haematologic and cytogenetic remissions in most patients with chronic phase CML (Druker *et al*, 2001; Deininger *et al*, 2009). However, a substantial proportion of patients with advanced phase CML or *BCR-ABL1* positive ALL are initially refractory to

1
2
3 imatinib treatment or lose imatinib sensitivity over time and relapse (Apperley, 2007; Pui *et*
4 *al*, 2008). More potent second-generation ABL1 kinase inhibitors (e.g. dasatinib, nilotinib,
5
6 *al*, 2008). More potent second-generation ABL1 kinase inhibitors (e.g. dasatinib, nilotinib,
7
8 bosutinib) have been developed for the treatment of imatinib-resistant patients and emerging
9
10 clinical data indicate that these drugs have promising efficacy (Weisberg *et al*, 2007, Gruber
11
12 *et al*, 2009). Both, first- and second-generation ABL1 kinase inhibitors are expected to
13
14 achieve similar remission rates in patients with *ABL1* fusion genes other than *BCR-ABL1*.
15
16 However, because the majority of these cases have only been reported in individual patients,
17
18 insufficient data on the *in-vivo* efficacy of tyrosine kinase inhibitors are currently available.
19
20
21
22 *NUP214-ABL* and *EML1-ABL* have been shown to be imatinib sensitive *in-vitro* and two
23
24 single case reports documented dasatinib sensitivity for *NUP214-ABL* and *RCSD1-ABL in-*
25
26 *vivo* (Deenik *et al*, 2009; Mustjoki *et al*, 2009).
27
28
29
30
31
32

33 In this study, we have investigated two B-ALL patients with acquired chromosomal
34
35 rearrangements each involving the chromosomal band 9q34 and identified two novel *ABL1*
36
37 fusion genes potentially sensitive to imatinib treatment. Although these fusion genes occur
38
39 rarely, their identification is essential in order to detect patients in whom targeted treatment
40
41 with tyrosine kinase inhibitors is likely to be successful. Furthermore, molecular definition of
42
43 novel fusion partners for known kinases remains important both for rapid molecular diagnosis
44
45 of new cases and for monitoring an individual patient's response to treatment.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patients and methods

Patients

Case 1: *FOXP1-ABL1* male/female B-ALL with t(3;9)(p12;q34).

A 16-year old caucasian woman was diagnosed with pre B cell acute lymphoblastic leukaemia in October 2001, with an initial white blood cell count of >50,000/nL. Her past medical history was significant only for recurrent deep venous thrombosis secondary to protein S deficiency. Bone marrow cytogenetics was 46XX,t(3;9)(p12;q34)[20]. FISH revealed loss of one copy of the p16 locus. Based on her age and an initial white blood count she was considered high risk. Treatment was initiated according to the standard arm for high risk patients of the COALL-97 protocol of the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL). Therapy was complicated by recurrent DVT, catheter-associated septicaemia and steroid-induced diabetes mellitus. She achieved a complete response and in February 2002 was consolidated with a haplo-identical transplant from her father. Complications included grade III GvHD of the skin and fungal pneumonia, both of which resolved on therapy. On last follow-up in spring of 2010 she continued in CR, with excellent functionality (attending medical school).

Case 2: *SNX2-ABL1* male B-ALL with t(5;9)(q23;q34).

The patient was diagnosed in April 2004 aged 29 when he presented with a WBC of 161 x10⁹/l. The cell showed a classical B-cell immunophenotype. Bone marrow cytogenetics showed a t(5;9)(q23;q34) and a 20q-. FISH showed evidence of the ABL gene on both derivative chromosomes. BCR was apparently not involved. He responded well to initial

1
2
3 chemotherapy but relapsed early. He then received hyper-C-VAD and again responded. He
4
5 relapsed again at the end of 2004 and was started on imatinib, it was transient and despite
6
7 other supportive measures including hydroxyurea he died in Spring 2005.
8
9

10 11 12 13 14 15 *Fluorescence In Situ Hybridization (FISH)*

16
17 To our knowledge, no other cases have been reported with a t(3;9)(p14;q34) or
18
19 t(5;9)(q23;q34). For the t(5;9) FISH was performed using the BCR-ABL probe from Abbott.
20
21
22
23
24
25
26

27 *5' Rapid Amplification of cDNA Ends (5' RACE) PCR*

28
29 Partner genes were identified using the Gene-Racer™ Kit (Invitrogen, Paisley, UK). Briefly,
30
31 ~ 5 µg of total RNA extracted using the Qiagen RNeasy kit (Qiagen, Boundary Court, UK)
32
33 was dephosphorylated, decapped, and ligated to the GeneRacer™ RNA oligo according to the
34
35 manufacturer's instructions. The ligated RNA was reverse transcribed using Superscript II™
36
37 reverse transcriptase (Invitrogen, Paisley, UK) and random primers (100 ng). Single step 5'
38
39 RACE PCR was performed using the 5' GeneRacer™ primer from the kit in combination with
40
41 a reverse primer from ABL1 exon 4 (1R: 5'-cca ccg ttg aat gat gat gaa cc-3'). The PCR cycles
42
43 were designed to amplify fragments up to 3 kb, with an annealing temperature of 66°C using
44
45 the High Fidelity PCR Master kit (Roche, Mannheim, Germany) according to the
46
47 manufacturer's instructions. Products were cloned with the TOPO TA Cloning Kit for
48
49 Sequencing (Invitrogen, Paisley, UK) and sequenced.
50
51
52
53
54
55
56
57
58
59
60

RT-PCR Methods

1
2
3 Case 1: The presence of FOXP1-ABL1 mRNA was confirmed on random hexamer reverse
4 transcribed cDNA using primers to FOXP1 exon 18 (5'-gca gta tgg aca gtg gat gaa gta-3')
5
6 with the reverse ABL1 exon 4 (see above). These primers were also used to amplify the
7
8 genomic breakpoint.
9
10

11
12
13
14
15 Case 2: The presence of SNX2-ABL1 mRNA was confirmed on random hexamer reverse
16 transcribed cDNA using primers to SNX2 1F new (5'-aag agt atg tct gct ccc gtg atc tt-3') with
17
18 the reverse ABL1 exon 4. These primers were also used to amplify the genomic breakpoint.
19
20
21

22 23 24 25 **Results**

26 27 28 29 *Characterization of the t(3;9)(p14;q34)*

30
31 FISH using the probes that immediately flank the ABL1 gene hybridized to the normal copy
32 of chromosome 9, also the der(9) and the der(3), indicating that the translocation targeted
33 ABL1; however, no BCR-ABL1 fusion was seen by FISH or RT-PCR. Most ABL1 fusions
34 reported to date result in the partner gene fusing to ABL1 exons 2 or 3. To identify the t(3;9)
35 partner, we, therefore, performed 5'-RACE PCR from both these exons. These initial attempts
36 failed despite the fact that normal 5' ABL1 sequence was readily obtained (data not shown).
37
38 5' RACE primers were subsequently designed in ABL1 exon 4 (ENST00000318560).
39
40 Sequencing of the products revealed several clones in which FOXP1 (ENST00000318789)
41
42 exon 19 was fused in frame to ABL1 exon 4.
43
44
45
46
47
48
49
50
51
52

53 54 55 *Confirmation of the FOXP1-ABL1 fusion*

56
57 The presence of the FOXP1-ABL1 fusion was confirmed initially by RT-PCR. The reciprocal
58
59 ABL1-FOXP1 product was detectable by single step PCR. Cloning and sequencing revealed
60

1
2
3 that the reciprocal product fuses ABL1 exon 3 to an alternative RNA isoform (NM_032682)
4 of FOXP1. As shown in Figure 1a and 1b, the FOXP1-ABL1 fusion was specifically
5 amplified from patient cells by single step PCR, but was not detectable in normal controls. To
6
7
8
9
10 further confirm the presence of the fusion the genomic breakpoint was amplified by long
11
12
13 PCR, cloned, and sequenced.

14 15 16 17 *Characterization of the t(5;9)(q23;q34)*

18
19 FISH using the Abbott BCR-ABL1 probes that immediately flank the ABL1 gene hybridized
20 to the normal copy of chromosome 9, also the der(9) and the der(5), indicating that the
21
22 translocation targeted ABL1; however, no BCR-ABL1 fusion was seen by FISH or RT-PCR.
23
24
25
26
27 5' RACE PCR from ABL1 exons 2 and 3 failed, after the previous cloning of the t(3;9)
28 translocation, 5'-RACE PCR primers were designed in ABL1 exon 4 (ENST00000318560).
29
30 Sequencing of the products revealed several clones in which SNX2 (ENST00000379516)
31
32
33
34 exon 3 was fused in frame to ABL1 exon 4.

35 36 37 38 *Confirmation of the SNX2-ABL1 fusion*

39
40 The presence of the SNX2-ABL1 fusion was confirmed initially by RT-PCR. The reciprocal
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155

Discussion

This study has characterised the genomic breakpoints in two B-ALL cases with chromosome 9q34 rearrangements and identified *FOXP1* at 3p14 and *SNX2* at 5q23 as novel *ABL1* fusion partners. This brings the number of known *ABL1* partner genes to nine. In the chimeric protein, N-terminal sequences of *ABL1* are replaced by amino-acids derived from the partner protein that provides dimerisation motifs essential for the transforming activity of *ABL1*. Fusion genes involving *ABL1* are excellent drug targets as exemplified by the activity of imatinib in *BCR-ABL1* positive diseases, particularly CML. The clinical course of patients with *ABL1* fusion genes other than *BCR-ABL1* may be different and highly dependent on the underlying disease. Response rates and risk of relapse may be similar to CML in patients with chronic phase myeloproliferative neoplasms or similar to *BCR-ABL1* positive ALL in patients with acute leukaemias, respectively. As the fusions described here were referred specifically for investigation of 9q rearrangements and were not part of a series that underwent systemic cytogenetic investigation, it is not possible to accurately determine the frequency of these abnormalities. However, we estimate that they probably account for <1% of ALL cases.

The *ABL1* gene is located on chromosome band 9q34 and encodes a ubiquitously cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Simplified, the structure of *ABL1* consists of N-terminal SH3 and SH2 domains (which mediate binding to proline-rich and phosphotyrosine protein ligands, respectively), a catalytic tyrosine kinase domain that contains phosphotransferase activity and a DNA-binding domain with yet largely unknown effects and a C-terminal actin-binding domain. Most previously described fusion genes involving *ABL1* fuse with *ABL1* exon 2. However, similar to the recently described fusion

1
2
3 partners *SFPQ* and *RCSD1* (Hidalgo-Curtis *et al*, 2008; Mustjoki *et al*, 2009) both partner
4
5 genes described here fuse to *ABL1* exon 4. These are structurally unusual *ABL1* fusion
6
7 proteins as the SH3 and SH2 domains are not included. Mouse models with BCR-ABL1
8
9 constructs in which the SH2 domain was inactivated have shown that the fusion protein
10
11 retained the ability to cause leukaemia in mice (Roumiantsev *et al*, 2001).
12
13
14
15
16

17 The *FOXP1* gene is located at 3p14 and encodes a member of the forkhead box (FOX) family
18
19 of transcription factors with diverse functions in development, metabolism, organogenesis and
20
21 cancer (Hannenhalli & Kaestner, 2009). *FOXP1* was first cloned from the mouse B-cell
22
23 leukaemia cell line BCL1 and later described to be an essential transcriptional regulator of B
24
25 lymphopoiesis via direct regulation of the B-cell specific Erag enhancer (Li & Tucker, 1993;
26
27 Hu *et al*, 2006). *FOXP1* has been described as a recurrent translocation partner of the IGH
28
29 gene in a subset of MALT lymphomas and diffuse large B-cell lymphomas with
30
31 t(3;14)(p14;q32) (Streubel *et al*, 2005; Wlodarska *et al*, 2005). Furthermore, *FOXP1* was
32
33 identified as a translocation partner of *PAX5* in a single case of paediatric B-ALL (Mullighan
34
35 *et al*, 2007). In contrast to previously published studies, we found *FOXP1* as the 5' partner of
36
37 the fusion gene. Nearly the entire *FOXP1* gene including the forkhead domain was fused in 5'
38
39 position to *ABL1*.
40
41
42
43
44
45
46
47

48 The *SNX2* gene is located at 5q23 and belongs to the sortin nexins (SNX) family that function
49
50 within the endocytic network, including endocytosis, endosomal sorting and endosomal
51
52 signalling (Cullen, 2008). *SNX2* is expressed at high levels in CD34 positive bone marrow
53
54 cells and thought to heterodimerise with *SNX1* in a retromer protein complex. The retromer is
55
56 a vesicle coat complex that helps in protein sorting between the Golgi and endosomes, playing
57
58 a key role in protecting some receptors from lysosomal destruction (Seaman, 2005). The
59
60 hallmark of SNX family is the presence of a PX domain - a sequence of approximately 100-

1
2
3 130 amino acids that has been shown to bind various phosphatidylinositol phosphates, thereby
4
5 potentially targeting these proteins to specific cellular membranes that are enriched in these
6
7 phospholipids (Worby & Dixon, 2002). As described above, constitutive activation of ABL
8
9 fusion genes is mediated by an oligomerisation domain in the partner protein. The *SNX2-*
10
11 *ABL1* fusion gene is unusual as it lacks a clearly recognisable dimerisation motif. The N-
12
13 terminal domain of SNX2 - without the PX domain - is fused to ABL1 exon 4.
14
15
16
17
18
19

20 Although rare the potential sensitivity to imatinib implies that these fusions should be
21
22 searched for in acute leukaemia. The screen for such uncommon, but clinically significant
23
24 fusion transcripts can easily be included in multiplex PCR panels used in routine diagnostic
25
26 work-ups. Targeted therapy has revolutionised the treatment of CML and there is considerable
27
28 optimism that targeting *ABL1* fusion genes other than *BCR-ABL1* will bring at least short term
29
30 benefits for those patients. On the other hand, targeted therapy is very expensive and it will be
31
32 important to develop markers to identify those patients who are most likely to benefit from
33
34 treatment.
35
36
37
38
39
40
41
42
43
44
45

46 **Acknowledgements**

47
48 TE was supported by the Dr Mildred Scheel Stiftung für Krebsforschung (Deutsche
49
50 Krebshilfe e.V.).
51
52
53
54
55
56
57
58
59
60


References

- 1
2
3
4
5
6 Andreasson, P., Johansson, B., Carlsson, M., Jarlsfelt, I., Fioretos, T., Mitelman, F. &
7 Hoglund, M. (1997) BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL
8 fusion. *Genes Chromosomes Cancer*, **20**, 299-304.
- 9 Apperley, J.F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid
10 leukaemia. *Lancet Oncol*, **8**, 1018-1029.
- 11 Ben-Neriah, Y., Daley, G.Q., Mes-Masson A.M., Witte, O.N. & Baltimore, D. (1986)
12 The chronic myelogenous leukemia-specific P210 protein is the product of the
13 bcr/abl hybrid gene. *Science*, **233**, 212-214.
- 14 Chase, A. & Cross, N.C. (2006) Signal transduction therapy in haematological malignancies:
15 identification and targeting of tyrosine kinases. *Clin Sci (Lond)*, **111**, 233-249.
- 16 Cullen, P.J. (2008) Endosomal sorting and signalling: an emerging role for sorting nexins. *Nat*
17 *Rev Mol Cell Biol*, **9**, 574-582.
- 18 De Braekeleer, E., Douet-Guilbert, N., Le Bris, M.J., Berthou, C., Morel, F. & De Braekeleer,
19 M. (2007) A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell
20 acute lymphoblastic leukemia. *Leukemia*, **21**, 2220-2221.
- 21 De Keersmaecker, K., Graux, C., Odero, M.D., Mentens, N., Somers, R., Maertens, J.,
22 Wlodarska, I., Vandenberghe, P., Hagemeyer, A., Marynen, P. & Cools, J. (2005)
23 Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic
24 t(9;14)(q34;q32). *Blood*, **105**, 4849-4852.
- 25 Deenik, W., Beverloo, H.B., van der Poel-van de Luytgaarde, S.C., Wattel, M.M., van Esser,
26 J.W., Valk, P.J. & Cornelissen, J.J. (2009) Rapid complete cytogenetic remission after
27 upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell
28 acute lymphoblastic leukemia. *Leukemia*, **23**, 627-629.
- 29 Deininger, M., O'Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P.,
30 Radich, J.P., Hatfield, A.K., Mone, M., Filian, J., Reynolds, J., Gathmann, I., Larson,
31 R.A. & Druker, B.J. (2009) International randomized study of interferon vs STI571
32 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in
33 patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
34 Treated with Imatinib. *Blood (ASH annual meeting abstracts)*, **114**, [1126].
- 35 Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B.,
36 Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and
37 safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
38 leukemia. *N Engl J Med*, **344**, 1031-1037.
- 39 Frohling, S. & Dohner, H. (2008) Chromosomal abnormalities in cancer. *N Engl J Med*, **359**,
40 722-734.
- 41 Golub, T.R., Goga, A., Barker, G.F., Afar, D.E., McLaughlin, J., Bohlander, S.K., Rowley,
42 J.D., Witte, O.N. & Gilliland, D.G. (1996) Oligomerization of the ABL tyrosine
43 kinase by the Ets protein TEL in human leukemia. *Mol Cell Biol*, **16**, 4107-4116.
- 44 Graux, C., Cools, J., Melotte, C., Quentmeier, H., Ferrando, A., Levine, R., Vermeesch, J.R.,
45 Stul, M., Dutta, B., Boeckx, N., Bosly, A., Heimann, P., Uyttbroeck, A., Mentens, N.,
46 Somers, R., MacLeod, R.A., Drexler, H.G., Look, A.T., Gilliland, D.G., Michaux, L.,
47 Vandenberghe, P., Wlodarska, I., Marynen, P. & Hagemeyer, A. (2004) Fusion of
48 NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. *Nat*
49 *Genet*, **36**, 1084-1089.
- 50 Gruber, F., Mustjoki, S. & Porkka, K. (2009) Impact of tyrosine kinase inhibitors on patient
51 outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. *Br J*
52 *Haematol*, **145**, 581-597.
- 53 Hannenhalli, S. & Kaestner, K.H. (2009) The evolution of Fox genes and their role in
54 development and disease. *Nat Rev Genet*, **10**, 233-240.
- 55
56
57
58
59
60


- 1
2
3 Hidalgo-Curtis, C., Chase, A., Drachenberg, M., Roberts, M.W., Finkelstein, J.Z., Mould, S.,
4 Oscier, D., Cross, N.C. & Grand, F.H. (2008) The t(1;9)(p34;q34) and
5 t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL
6 and FGFR1. *Genes Chromosomes Cancer*, **47**, 379-385.
- 7
8 Hu, H., Wang, B., Borde, M., Nardone, J., Maika, S., Allred, L., Tucker, P.W. & Rao, A.
9 (2006) Foxp1 is an essential transcriptional regulator of B cell development. *Nat*
10 *Immunol*, **7**, 819-826.
- 11
12 Li, C. & Tucker, P.W. (1993) DNA-binding properties and secondary structural model of the
13 hepatocyte nuclear factor 3/fork head domain. *Proc Natl Acad Sci U S A*, **90**, 11583-
14 11587.
- 15
16 Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D.,
17 Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V.,
18 Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of
19 genetic alterations in acute lymphoblastic leukaemia. *Nature*, **446**, 758-764.
- 20
21 Mustjoki, S., Hernesniemi, S., Rauhala, A., Kahkonen, M., Almqvist, A., Lundan, T. &
22 Porkka, K. (2009) A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in
23 chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
24 *Haematologica*, **94**, 1469-1471.
- 25
26 Papadopoulos, P., Ridge, S.A., Boucher, C.A., Stocking, C. & Wiedemann, L.M. (1995) The
27 novel activation of ABL by fusion to an ets-related gene, TEL. *Cancer Res*, **55**, 34-38.
- 28
29 Pui, C.H., Robison, L.L. & Look, A.T. (2008) Acute lymphoblastic leukaemia. *Lancet*, **371**,
30 1030-1043.
- 31
32 Roumiantsev, S., de Aos, I.E., Varticovski, L., Ilaria, R.L. & Van Etten, R.A. (2001) The src
33 homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid
34 leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of
35 phosphatidylinositol 3-kinase. *Blood*, **97**, 4-13.
- 36
37 Seaman, M.N. (2005) Recycle your receptors with retromer. *Trends Cell Biol*, **15**, 68-75.
- 38
39 Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. (1985) Fused transcript of abl and bcr
40 genes in chronic myelogenous leukaemia. *Nature*, **315**, 550-554.
- 41
42 Soler, G., Radford-Weiss, I., Ben-Abdelali, R., Mahlaoui, N., Ponceau, J.F., Macintyre, E.A.,
43 Vekemans, M., Bernard, O.A. & Romana, S.P. (2008) Fusion of ZMIZ1 to ABL1 in a
44 B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation.
45 *Leukemia*, **22**, 1278-1280.
- 46
47 Streubel, B., Vinatzer, U., Lamprecht, A., Raderer, M. & Chott, A. (2005) T(3;14)(p14.1;q32)
48 involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT
49 lymphoma. *Leukemia*, **19**, 652-658.
- 50
51 Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. & Griffin, J.D. (2007)
52 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant
53 chronic myeloid leukaemia. *Nat Rev Cancer*, **7**, 345-356.
- 54
55 Wlodarska, I., Veyt, E., De Paepe, P., Vandenberghe, P., Nooijen, P., Theate, I., Michaux, L.,
56 Sagaert, X., Marynen, P., Hagemeyer, A. & De Wolf-Peeters, C. (2005) FOXP1, a
57 gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently
58 targeted by genomic aberrations. *Leukemia*, **19**, 1299-1305.
- 59
60 Worby, C.A. & Dixon, J.E. (2002) Sorting out the cellular functions of sorting nexins. *Nat*
Rev Mol Cell Biol, **3**, 919-931.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

t(3;9) N1 N2 N3 B1 B2



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

t(5;9) N1 N2 N3 B1

1 kb →
500 bp →

